A risk-based approach is the foundation for designing a viral shedding study for an Advanced Therapy Medicinal Product (ATMP) under Swissmedic regulations. The assessment framework is not prescriptive; it requires a scientifically justified strategy based on vector characteristics (e.g., replication competence), route of administration, and the target patient population. A well-designed study generates the necessary data to evaluate potential transmission risk to close contacts and the environment, satisfying regulatory expectations for clinical trial applications.
What are Swissmedic’s primary concerns for viral shedding in ATMPs?
Swissmedic’s evaluation centers on patient safety, potential environmental release, and the risk of transmission to healthcare providers and close contacts. The core technical concerns involve the vector’s capacity for replication, its persistence in various tissues, and the potential for recombination or shedding of replication-competent particles, even from a replication-incompetent starting product.
How does the ATMP vector type influence the shedding study design?
The vector is the primary determinant of risk. A replication-competent vector, such as an oncolytic virus, requires a more extensive and prolonged shedding assessment than a replication-incompetent vector, like most adeno-associated virus (AAV) constructs. For AAVs, the study focuses on quantifying the clearance of vector genetic material from excreta and secreta, whereas for replication-competent products, the analysis must also detect infectious viral particles.
What sample matrices are typically required for a viral shedding study in Switzerland?
Matrix selection is dictated by the route of administration and preclinical non-target tissue biodistribution data. Common matrices include blood (plasma/serum), urine, saliva, and feces. Depending on the product and delivery method, additional samples may be justified, such as swabs from an injection site, tears, or respiratory secretions for inhaled vectors.
Is a quantitative or qualitative assay required for shedding analysis?
Quantitative assays, primarily quantitative PCR (qPCR) or droplet digital PCR (ddPCR), are the standard for viral shedding studies. These methods are necessary to determine the concentration of shed vector genetic material over time and model the clearance kinetics. This quantitative data is fundamental for risk assessment and for defining appropriate patient management instructions.
